Amgen has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. The terms of the agreement include a $50 million upfront payment, $385 million in success-based milestones and additional sales based milestones and royalties on sales. The agreement provides OMJPI with global rights to the product, but excludes Japan, where Amgen has entered into a previous license agreement wit...